Immunotherapies, especially CAR T-cell therapy, have fundamentally changed cancer treatment in recent years, particularly for certain forms of leukemia and lymphoma. Yet not all tumors respond equally well, and the reasons for this remain incompletely understood. A new multicenter study by the Leibniz Institute for Immunotherapy collaboration group, Innate Immune Sensing in Cancer and Transplantation, now shows that it is not only the compositio…